Under one in 10 people that would benefit from obesity jabs including Wegovy are able to get them, states the WHO as it publishes its initial recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging more widespread and fairer availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidance acknowledges that obesity is a chronic disease that can be managed with comprehensive and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are key barriers to universal availability to the jabs that can aid individuals in losing considerable body mass, says the agency.
Skinny Jab Shortage
Even in the present best projected outlook, the manufacturing of such drugs could only cover about 100 million people – under 10% of those who need them, per the health organization.
The recommendation calls on nations and manufacturers to widen availability, via approaches including voluntary licensing.
Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is due to expire in a number of countries in 2026.
How Weight-Loss Jabs Function
The injections replicate a natural hormone to reduce digestion speed, curb appetite and boost satiety so people consume fewer calories.
Individuals commonly begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Evidence indicates users may put most of the weight back on a year later of discontinuing the treatment, because their typical appetite come back.
Being above a healthy weight elevates your likelihood for developing diseases, such as diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
